Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Epizyme Inc (EPZM)

Epizyme Inc (EPZM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,382,503
  • Shares Outstanding, K 91,074
  • Annual Sales, $ 21,700 K
  • Annual Income, $ -123,630 K
  • 60-Month Beta 2.40
  • Price/Sales 60.44
  • Price/Cash Flow N/A
  • Price/Book 5.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.52
  • Number of Estimates 7
  • High Estimate -0.45
  • Low Estimate -0.63
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -79.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.88 +50.35%
on 10/15/19
15.25 -2.59%
on 11/11/19
+4.82 (+48.11%)
since 10/11/19
3-Month
9.73 +52.67%
on 10/09/19
15.25 -2.59%
on 11/11/19
+3.35 (+29.17%)
since 08/09/19
52-Week
5.14 +189.01%
on 12/24/18
16.59 -10.46%
on 06/24/19
+7.10 (+91.68%)
since 11/09/18

Most Recent Stories

More News
Look for Shares of Epizyme Inc to Potentially Pullback after Yesterday's 41.26% Rise

Epizyme Inc (NASDAQ:EPZM) traded in a range yesterday that spanned from a low of $14.13 to a high of $15.12. Yesterday, the shares gained 41.3%, which took the trading range above the 3-day high of $14.55...

EPZM : 14.85 (-2.14%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (EPZM , HALO , FGEN , KPTI , REGN )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

EPZM : 14.85 (-2.14%)
FGEN : 35.40 (-14.94%)
HALO : 16.60 (-1.60%)
Royalty Pharma Announces Agreement to Purchase Future Royalties on Tazemetostat from Eisai for $330 Million and a $100 Million Initial Investment in Epizyme

Royalty Pharma announced today that it has agreed to pay $330 million to purchase Eisai Co., Ltd.'s royalties on future worldwide sales of tazemetostat, Epizyme Inc.'s (Nasdaq: EPZM) lead investigational...

EPZM : 14.85 (-2.14%)
Epizyme Establishes Agreements for Up to $270 Million in Funding to Support Tazemetostat Commercialization and Pipeline Advancement

--Existing Royalty Obligation on Future Tazemetostat Sales Reduced with Royalty Pharma

EPZM : 14.85 (-2.14%)
Shares of Epizyme Inc Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (EPZM , INSM , PTCT , UTHR , IONS )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

EPZM : 14.85 (-2.14%)
INSM : 18.92 (-0.79%)
PTCT : 41.30 (+0.29%)
Watch for Epizyme Inc to Potentially Pullback After Gaining 12.69% Yesterday

Epizyme Inc (NASDAQ:EPZM) traded in a range yesterday that spanned from a low of $10.70 to a high of $11.59. Yesterday, the shares gained 12.7%, which took the trading range above the 3-day high of $11.24...

EPZM : 14.85 (-2.14%)
Epizyme (EPZM) Reports Q3 Loss, Tops Revenue Estimates

Epizyme (EPZM) delivered earnings and revenue surprises of 25.93% and 3.91%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

EPZM : 14.85 (-2.14%)
Epizyme: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Epizyme Inc. (EPZM) on Wednesday reported a loss of $36.1 million in its third quarter.

EPZM : 14.85 (-2.14%)
Epizyme Announces Positive Pre-NDA Meeting for Tazemetostat for Follicular Lymphoma, Pipeline Updates and Third Quarter 2019 Results

--Updated Phase 2 Follicular Lymphoma Data Selected for Oral Presentation at ASH

EPZM : 14.85 (-2.14%)
Epizyme (EPZM) Shares Cross Below 200 DMA

In trading on Wednesday, shares of Epizyme Inc. crossed below their 200 day moving average of $11.66, changing hands as low as $11.33 per share.

EPZM : 14.85 (-2.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade EPZM with:

Business Summary

Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 15.61
1st Resistance Point 15.23
Last Price 14.85
1st Support Level 14.49
2nd Support Level 14.13

See More

52-Week High 16.59
Last Price 14.85
Fibonacci 61.8% 12.22
Fibonacci 50% 10.86
Fibonacci 38.2% 9.51
52-Week Low 5.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar